Due to its key role in initiating platelet‐leukocyte interactions, P‐selectin has emerged as a therapeutic target to reduce thrombosis in many thrombo‐inflammatory diseases including DVT95 and sickle cell disease. This evidence concerns the gene SELP and sickle cell disease.